- Trials with a EudraCT protocol (117)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
117 result(s) found for: Vital statistics.
Displaying page 1 of 6.
EudraCT Number: 2014-005555-80 | Sponsor Protocol Number: V00400SB302 | Start Date*: 2015-05-21 | |||||||||||
Sponsor Name:Pierre Fabre Dermatologie represented by IRPF | |||||||||||||
Full Title: Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study | |||||||||||||
Medical condition: High risk infantile haemangioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004019-34 | Sponsor Protocol Number: ABI-H0731-211 | Start Date*: 2019-02-20 |
Sponsor Name:Assembly Biosciences | ||
Full Title: A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients | ||
Medical condition: Chronic Hepatitis B | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2012-004072-19 | Sponsor Protocol Number: Acti-INSP-001 | Start Date*: 2012-12-28 | |||||||||||
Sponsor Name:Vectura GmbH | |||||||||||||
Full Title: A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patie... | |||||||||||||
Medical condition: Influenza A and B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001374-34 | Sponsor Protocol Number: 6630-0450-01 | Start Date*: 2014-06-11 |
Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG | ||
Full Title: A monocentric, observer-blind, randomized clinical study using an abrasive wound model with an intra-individual comparison to investigate the wound healing properties of a topical wound healing pro... | ||
Medical condition: healthy volunteers; intended indication is the treatment of acute wounds such as abrasions, cuts, scratches, laceration, blistering burns and sunburns | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005615-92 | Sponsor Protocol Number: CQBM076X2203 | Start Date*: 2013-11-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) NL (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005552-15 | Sponsor Protocol Number: 20120325 | Start Date*: 2015-05-18 |
Sponsor Name:Amgen Inc. | ||
Full Title: A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Immunoprofile Intratumoral CD8+ Cell Density in Subjects With Unresecte... | ||
Medical condition: Unresected stage IIIB to IVM1c melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) ES (Completed) DE (Completed) BE (Completed) AT (Completed) HU (Completed) PL (Completed) GR (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000361-78 | Sponsor Protocol Number: HTA-HUR-01 | Start Date*: 2020-12-01 |
Sponsor Name:HOLOSTEM TERAPIE AVANZATE S.R.L. | ||
Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED ORAL MUCOSA GRAFTS FOR URETHRAL RECONSTRUCTION IN PATIENTS DUE TO HYPOSPADIAS TREATMENT... | ||
Medical condition: Urethral reconstruction in patients due to hypospadias treatment failure. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004207-52 | Sponsor Protocol Number: CQGE031C2202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneou... | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) BE (Completed) HU (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000574-40 | Sponsor Protocol Number: PSP-CoQ10 | Start Date*: 2006-04-24 |
Sponsor Name:Kompetenznetz Parkinson e.V. | ||
Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® | ||
Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002038-33 | Sponsor Protocol Number: LIBERTY | Start Date*: 2020-07-16 |
Sponsor Name:Porin kaupunki | ||
Full Title: Controlled clinical trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting | ||
Medical condition: Covid-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001101-40 | Sponsor Protocol Number: 13/0417 | Start Date*: 2015-02-24 | ||||||||||||||||
Sponsor Name:University College London (UCL) | ||||||||||||||||||
Full Title: Sclero XIII: A phase II ,double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic... | ||||||||||||||||||
Medical condition: Systemic Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004822-15 | Sponsor Protocol Number: GNC-401 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:GeNeuro Innovation SAS | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003799-15 | Sponsor Protocol Number: ACE1100-01 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Ascelia Pharma AB | |||||||||||||
Full Title: A Randomized, Double-blind Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of ASC-201 Plus Trifluridine/Tipiracil Compared With Trifluridine/Tipiracil in Patients With Adv... | |||||||||||||
Medical condition: Advanced Gastric Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001185-14 | Sponsor Protocol Number: M04-724 | Start Date*: 2005-06-01 |
Sponsor Name:Abbott GmbH & Co. KG | ||
Full Title: Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient S... | ||
Medical condition: Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DE (Completed) SE (Completed) DK (Completed) GB (Completed) IE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001516-19 | Sponsor Protocol Number: 156-13-211 | Start Date*: 2015-03-26 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, | |||||||||||||
Full Title: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant ... | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) SE (Completed) NL (Completed) BE (Completed) PL (Completed) ES (Completed) CZ (Completed) HU (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004713-15 | Sponsor Protocol Number: 1235-SR-1005 | Start Date*: 2006-02-02 |
Sponsor Name:Cardiome Pharma Corp. | ||
Full Title: A Pilot Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flut... | ||
Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) CZ (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002385-23 | Sponsor Protocol Number: AFT-MXCF-03 | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:AFT Pharmaceuticals Ltd | |||||||||||||
Full Title: A phase 3 randomised, double blind, multiple dose, parallel group efficacy study of different doses of phenylephrine hydrochloride combined with paracetamol and/or ibuprofen in participants with na... | |||||||||||||
Medical condition: nasal congestion | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002034-47 | Sponsor Protocol Number: AF219-014 | Start Date*: 2015-10-12 |
Sponsor Name:Afferent Pharmaceuticals, Inc. | ||
Full Title: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects | ||
Medical condition: Chronic cough | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003064-47 | Sponsor Protocol Number: CUDC-101-104 | Start Date*: 2012-12-11 | |||||||||||
Sponsor Name:Curis, Inc. | |||||||||||||
Full Title: A Phase 1 open-label study to investigate the pharmacodynamics, metabolomics and pharmacokinetics of CUDC-101 in subjects with HER2 positive invasive breast cancer. | |||||||||||||
Medical condition: HER2 positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001859-36 | Sponsor Protocol Number: PRS-2011-03 | Start Date*: 2011-07-07 |
Sponsor Name:Meditop Pharmaceuticals Co. Ltd. | ||
Full Title: Clinical study on the insulin sensitizing effect of multiple administration of Vition (Meditop) in healthy human volunteers (Pilot study) | ||
Medical condition: Low potassium and magnesium levels especially in chronic heart disease. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
